Mark is the founder of PHMR and has developed the company into a successful health economics, pricing and market access consultancy working with a range of top 10 pharma companies. He has a vast amount of experience in the health economics, pricing, reimbursement and market access fields. He also possesses decades of experience with major international pharmaceutical companies and previous work in senior economics research positions.

Michael is involved across a range of health economics, outcomes research and market access projects at PHMR. As chief operating officer at PHMR, he is responsible for ensuring that the research delivered matches the strategic needs of our clients. Michael has extensive experience in the development of health economic models and indirect treatment comparisons, utility measurement and health valuation, strategies for collection and use of real-world data, and the development of dossiers to support HTA submission. He also has substantial experience in working with different stakeholders, including through the use of early scientific advice through HTA agencies, to lead the development of integrated evidence plans and allow for access needs to be incorporated from early in product development. Michael has led projects across many different therapeutic areas, with expertise in fields including oncology, gastroenterology, neuroscience, rare disease, and cardiovascular disease. Michael has also published his research in peer-reviewed journals and presented work at multiple international conferences. He has led educational initiatives to shape HTA policy, which involved delivering symposiums at international conferences and developing publications to support the use of innovative methodologies to demonstrate the value of new immuno-oncology medicines.

Koonal is a health economist with expertise in stated preference methods, the measurement and valuation of health, and the use of social value judgements in HTA decision making. He has written extensively on patient-reported outcomes and HTA policy (focusing on the assessment of cancer and end of life treatments) and has published over 40 peer-reviewed journal articles and book chapters. He has led high-profile projects across a broad range of clinical and methodological areas, with his work on the generation and analysis of utility values used in a large number of HTA submissions. Koonal is a member of the EuroQol Group (an international network of researchers that developed the EQ-5D family of instruments) and currently serves on the Group’s Executive Committee. He is also an Honorary Research Fellow at the University of Sheffield’s School of Health and Related Research.

Matt is a health economist with extensive experience in conducting economic evaluations of new treatments and specialises in long-term modelling, with knowledge of a variety of software and conceptual models. He has contributed to and advised biopharma clients on submissions to a number of HTA agencies. He has also contributed health economic input to the design of numerous randomised controlled trials and analysed and synthesised trial data.

Frauke is an experienced health economics and outcomes researcher with a strong background in advanced econometric methods. She has a wealth of knowledge in health technology assessment and preference elicitation in a range of settings. Frauke has conducted research in academia in both the United Kingdom and Germany for more than 15 years, having contributed to the development and health economic design of numerous randomised controlled trials. She has been a member of several guideline development groups, providing health economic input to clinical guidelines for NICE in the United Kingdom.

Megan has conducted a wide range of statistical analyses, such as indirect treatment comparisons and real-world evidence synthesis, including network meta-analyses, matching-adjusted indirect comparisons, and large patient-level health record analyses. She is experienced in many common and novel statistical methods used in the pharmaceutical industry and utilises both frequentist and Bayesian frameworks. She is also proficient with multiple programming languages, including SAS, R, and WinBUGS. Megan has published research in peer-reviewed journals and presented work at international conferences in several therapeutic areas, including oncology, rare diseases, and cardiology. Megan is a member of the Royal Statistical Society and is working towards Chartered Statistician status.

Rebecca is a market access researcher with expertise in project management of HTA reviews and systematic, targeted, and pragmatic reviews. Rebecca has extensive experience in performing reviews of clinical, economic, utilities, and real-world evidence with the aim of supporting HTA submissions. Rebecca has also performed HTA reviews and analysed pricing and reimbursement data to provide strategic recommendations. Rebecca has contributed to the writing of multiple manuscripts, abstracts, poster presentations, and slide decks for a variety of audiences. She has experience in multiple disease areas including nutrition, ageing, gastrointestinal disease, musculoskeletal disease, and rare diseases. Rebecca holds a PhD in ageing and health from Newcastle University.

An experienced health economist, Henrique develops market access and pricing strategies for clients while also contributing to health economics and HTA projects. Henrique has worked in market access, health economics, and pricing within consultancy and the pharmaceutical industry in the United Kingdom, Portugal, and France, leading market access projects in Europe and key markets outside Europe. He has particular experience with the development of global value dossiers and value messages to drive these dossiers, as well as in the development of strategic evidence plans and economic tools to communicate value. In addition, Henrique’s experience of working at Infarmed (the Portuguese HTA authority) gives him an acute understanding of HTA and payer needs that inform all of his work. Henrique has a PharmD in pharmaceutical sciences from the Universidade Lusófona de Humanidades e Tecnologias and an MSc in health economics from the University of York.

India has managed a range of health economic and outcomes research projects at PHMR. Her expertise enables her to conduct both quantitative and qualitative research, including mapping methods for estimation of health state utility, analysis of patient-reported outcomes, patient preference studies, and the development and execution of feasibility assessments. She has also supported the building and reviewing of economic models such as cost-effectiveness and budget impact models. India has worked across a variety of disease areas, including rare diseases and epilepsy. India holds an MSc in health economics from the University of York.

Daniella is a market access researcher who develops global value dossiers and conducts systematic and targeted literature reviews that generate evidence for HTA submissions. Daniella has experience in several disease areas, including neurology, renal disease, and oncology. Daniella’s interest in market access across Europe has informed a variety of HTA projects and development of training materials, as well as the PHMR monthly Market Access Alert service, which aims to keep clients informed on HTA decisions and key updates in the United Kingdom, Germany, and France.

Louise has considerable experience in all stages of systematic and targeted literature reviews to inform HTA decisions and has worked on a broad range of projects in multiple disease areas, including oncology, neurology, and renal disease. Louise has a keen interest in value communications and contributes to the development of global value dossiers to help our clients demonstrate the value of their products. Louise is also involved in PHMR’s monthly Market Access Alert service, which allows clients to keep up to date with HTA decisions. Louise holds a PhD in nutrition.

Nicola has conducted focussed and pragmatic literature reviews and contributed to projects on clinical trial design and burden of illness studies, global HTA strategies and the use of patient reported outcome measures in HTA. Nicola has extensive experience in clinical trial method development and has developed skills in data extraction and data management, presenting reports in the form of slide decks or word documents, as well the preparation of manuscripts and posters.

Involved in a range of projects, Gabriel has extensive experience of carrying out systematic and pragmatic literature reviews to support submissions to multiple European HTA agencies. As a market access researcher, he has also contributed to reviews to support the value proposition of technologies in global markets and help clients understand the value of their portfolio of products. Gabriel has worked on global value dossiers to support market access of technologies in Europe, North America, and emerging markets, as well as HTA reviews to understand evidence requirements for approval and reimbursement of combination therapies and highly specialised treatments. Gabriel helped to develop PHMR's Market Access Alert service and has been published in high-impact journals. He has also presented work at international conferences in the areas of oncology, endocrinology, and infectious disease.

Laura copyedits and proofreads PHMR’s written materials to the standards required by clients, peer-reviewed journals, and professional organisations. She has extensive experience in publishing and market access consultancies, preparing journal articles for publication and presentations for international conferences. Laura is certified by the Board of Editors in the Life Sciences.

Thomas is a statistician and supports market access through real-world evidence studies and indirect treatment comparisons. In particular, he has conducted several Bayesian network-meta analyses and matching-adjusted indirect comparisons in areas including cardiovascular disease, oncology, and neurology. In addition, he has published in peer-reviewed journals on the development of methodologies and in support of market access and post-market access activities. Thomas has been involved in the development of real-world evidence strategies and is proficient in R, Stata, and Python programming languages.

Helen leads the development of value propositions and global value dossiers. She has worked across a wide range of therapeutic areas, including oncology, chronic kidney disease, metabolic disorders, and bladder/bowel health. She is also experienced in conducting systematic literature reviews to support HTA submission and preparing HTA submission dossiers. Helen applies her expert medical writing skills to a broad range of projects at PHMR, including published manuscripts, posters and slide decks.

Aurélie is a health economist with broad experience in economic evaluation who has contributed to a variety of projects to support clients' needs from development of health economic models for HTA submissions to payer tools for engagement with national and local payers. Her expertise also stretches to mapping studies and value frameworks in the cell, gene, and rare disease spaces. Aurélie has broad knowledge of HTA methods and of a variety of statistical software packages.

Anne-Sophie has a wide-ranging experience of health economics and HTA in a range of settings including consultancies, hospitals, pharmaceutical companies and governmental bodies. Such wide-ranging experience has provided her with an in-depth understanding of HTA and reimbursement of pharmaceuticals. Anne-Sophie has developed many HTA submissions for the French HAS (Haute Autorité de Santé) for a range of new therapies including for oncology and orphan designation treatments on behalf of leading pharmaceutical companies. Prior to joining PHMR, Anne-Sophie worked at the Health Products Economics Committee (CEPS) of the French Ministry of Health where she developed valuable insight and experience in pricing processes and negotiations, and evaluation of economic dossiers.

Rachel is involved in the development of innovative, strategy-based value communications to support market access. She has a particular interest in the use of creative design and digital media to optimise the usability and impact of value communication materials. Rachel has experience in global value dossier development, treatment landscape analysis, reimbursement pathway mapping, literature reviews, peer-reviewed manuscript development, and stakeholder engagement through advisory boards and interviews. She has knowledge in multiple therapeutic areas, including inflammatory bowel disease, antineutrophil cytoplasmic autoantibody–associated vasculitis, cystic fibrosis, and renal disease, and a research and publishing background in nutrition and nutraceuticals. Rachel has a PhD in biological psychology from Northumbria University.

Ally is involved in a variety of projects at PHMR to help clients achieve optimal pricing and reimbursement. She has substantial experience in targeted and systematic literature reviews, research and data interpretation, and communicating complex information in slide decks and scientific reports. Ally has delivered multiple project types including reviews of clinical efficacy, burden of illness and HTA processes, mapping of pricing and reimbursement pathways, treatment landscape analysis, stakeholder interviews, strategic recommendations, value message development, and global value dossiers. She has disease area experience in oncology, infectious disease, chronic kidney disease, chronic inflammatory and autoimmune conditions, muscle wasting, and rare diseases. Ally holds a PhD in cellular biology and tissue engineering from Durham University.

Lucy is a market access researcher who has participated in conducting systematic and HTA literature reviews, including screening, data extraction, and quality assessment. She has considerable experience in quantitative and qualitative research. Lucy holds a PhD in public health nutrition from the University of Aberdeen.

Alexandra is a health economics and outcomes researcher with experience in health state valuation, utility measurement, and mapping studies. She has provided clients with advice on strategies for collecting and analysing patient-reported outcomes data in disease areas characterised by fluctuating health-related quality of life. She has also applied her expertise in mapping approaches to support clients’ needs for obtaining utility data required for their HTA submissions. In addition, Alexandra has led work to assess partitioned survival models and Markov models in the context of advanced non-small cell lung cancer. She has an MSc in health economics and decision modelling from the University of Sheffield.

Craig has extensive experience in conducting systematic and pragmatic literature reviews of clinical and economic evidence with quantitative data analyses to inform HTA submissions and other market access and reimbursement activities. Craig has also been involved in the development of value stories and global value dossiers, helping our clients build value for their products. He has experience in several disease areas including oncology, epilepsy, hyperkalaemia, and genetic disorders, and has published peer-reviewed research on neuroendocrine tumours. Craig holds a PhD in the broad area of food sustainability from Newcastle University.

Dimitris is a health economist with broad experience in economic evaluations of therapeutic and diagnostic interventions. He has led and contributed to the conceptualisation and development of cost-effectiveness and budget impact models using a wide range of software. Dimitris has completed a number of projects for a diverse range of funders and clients, including research foundations, pharmaceutical companies, and medical device companies. Dimitris has also conducted systematic literature reviews and diagnostic meta-analyses, and he has broad knowledge of HTA methods and processes. His work covers a wide range of disease areas, including oncology, mental health, metabolic diseases, and rare diseases.

Catherine has contributed to a wide range of clinical and economic literature reviews, adopting both pragmatic and systematic approaches. She has supported projects across several therapeutic areas, including oncology, epilepsy, and inflammatory bowel disease, applying extensive prior experience from a clinical trial background. Catherine has assisted in the publication of peer-reviewed research on neuroendocrine tumours and holds a PhD in neuroscience from Newcastle University.

Ed is a health economist with extensive experience in health technology assessment and decision analytic modelling across many therapeutic areas. He has worked at the Universities of York, Cambridge, and East Anglia and published more than 100 peer-reviewed journal articles and book chapters. In addition, Ed has served as a technology appraisal committee member for NICE. He is particularly interested in the value of information analysis (a statistical technique to estimate the return on investment in future research) and expert elicitation (a method to investigate experts’ opinions about plausible values for model parameters in the absence of data). Ed is a member of ConVOI, an international network of experts committed to developing and increasing uptake of value of information methods.